Lucid Diligence Brief: Zelgen × AbbVie option-to-license on alveltamig
Lucid Diligence Brief: Zelgen × AbbVie option-to-license on alveltamig…
Lucid Diligence Brief: Gilead licenses Assembly Bio’s HSV helicase-primase programs
Lucid Diligence Brief: Gilead licenses Assembly Bio’s HSV helicase-primase…
Lucid Diligence Brief: Sanofi moves to buy Dynavax for $2.2B
Lucid Diligence Brief: Sanofi moves to buy Dynavax for $2.2B Professional…
Lucid Diligence Brief: Neurable raises $35M Series A to scale brain-signal AI
Lucid Diligence Brief: Neurable raises $35M Series A to scale brain-signal AI…
Lucid Diligence Brief: Truemed $34m Series A to scale payment integration platform
Lucid Diligence Brief: Truemed $34m Series A to scale payment integration…
Lucid Diligence Brief: Jacobio and AstraZeneca pan-KRAS asset deal
Lucid Diligence Brief: Jacobio and AstraZeneca pan-KRAS asset deal Professional…
Lucid Diligence Brief: BioMarin to acquire Amicus Therapeutics for $4.8B
Lucid Diligence Brief: BioMarin to acquire Amicus Therapeutics for $4.8B…
Lucid Diligence Brief: Syremis Therapeutics launches with $165M Series A in schizophrenia
Lucid Diligence Brief: Syremis Therapeutics launches with $165M Series A in…
Lucid Diligence Brief: BioNTech completes acquisition of CureVac
Lucid Diligence Brief: BioNTech completes acquisition of CureVac Professional…
Lucid Diligence Brief: Prolynx $70m Series A for long-acting obesity candidates
Lucid Diligence Brief: Prolynx $70m Series A for long-acting obesity……
Lucid Diligence Brief: Insilico-TaiGen CKD anemia licensing deal
Lucid Diligence Brief: Insilico-TaiGen CKD anemia licensing deal Professional…
Lucid Diligence Brief: Pfizer YaoPharma oral GLP-1 deal
Lucid Diligence Brief: Pfizer YaoPharma oral GLP-1 deal Professional audiences…